Cover Image
市場調查報告書

Fc蛋白質及Glycoengineered抗體市場 (第2版) :2013∼2023年

Fc Protein and Glycoengineered Antibodies Market (2nd Edition), 2016 - 2026

出版商 ROOTS ANALYSIS 商品編碼 283284
出版日期 內容資訊 英文 327 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Fc蛋白質及Glycoengineered抗體市場 (第2版) :2013∼2023年 Fc Protein and Glycoengineered Antibodies Market (2nd Edition), 2016 - 2026
出版日期: 2016年03月31日 內容資訊: 英文 327 Pages
簡介

基因工程抗體的概念廣泛地用於生技改良藥/生技仿製藥的開發,處理先前藥物候補的缺點。幾個企業對於那樣的基因工程抗體的製造,開發、利用獨有的技術。此事,助長該領域許多授權活動、開創機會,構築小規模及龍頭醫藥品企業的強力的合作網路。

本報告提供Fc蛋白質基因工程抗體及Glycoengineered抗體市場 拿起,中短期的 (2016-2021年 及長期 (2021-2026年) 的市場預測、機會分析提供,認證藥、後期開發階段 (第三階段) 的藥物的潛在銷售額預測,近幾年的合作趨勢等彙整資料。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 本章概要
  • 單株抗體
  • 抗體為基礎的治療
  • 基因工程抗體的優點

第4章 市場概要

  • 本章概要
  • Glycoengineered抗體:開發平台
  • Fc蛋白質基因工程抗體:開發平台

第5章 Glycoengineered抗體市場

  • 本章概要
  • Kyowa Hakko Kirin
  • Roche
  • TG Therapeutics
  • MedImmune/AstraZeneca
  • LFB Biotechnologies
  • Glycotope

第6章 Fc蛋白質基因工程抗體市場

  • 本章概要
  • Roche/Genentech
  • Astra Zeneca/MedImmnune
  • Mentrik Biotech
  • MacroGenics
  • Janssen Biotech (Johnson and Johnson)
  • MorphoSys

第7章 市場預測、機會分析

  • 本章概要
  • 範圍、限制
  • 預測手法
  • Fc蛋白質、Glycoengineered抗體整體市場
  • Glycoengineered抗體市場預測
  • Fc蛋白質基因工程抗體市場預測

第8章 基因工程抗體開發的技術平台

  • 本章概要
  • POTELLIGENT (BioWa, Kyowa Hakko Kirin子公司)
  • GlycoMab 技術 (GlycArt)
  • GlycoExpress (Glycotope)
  • GlymaxX 技術 (ProBioGen)
  • XmAb 抗體技術 (Xencor)
  • 其他

第9章 近幾年的發展趨勢

  • 本章概要
  • 聯盟模式/協定
  • 近幾年的合作
  • 近幾年的合作:各月/年度的分佈
  • 近幾年的合作:治療應用模式的各類型的分佈
  • 近幾年的合作:各產品類型的分佈
  • 近幾年的合作:複數的合作最活躍的企業

第10章 SWOT分析

第11章 結論

  • 後期開發階段的幾個分子開發平台順利
  • 基因工程抗體:生技改良藥的開發平台
  • 透過確立的技術,企業穩定擴大開發平台
  • 聯盟的增加:對幾個醫藥品企業來說富有魅力的機會
  • 整體市場的龐大成長潛力
  • 總論

第12章 採訪

第13章 附錄1:圖表

第14章 附錄2:企業、機關清單

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA10058

Developed through introduction of modifications in monoclonal antibodies (mAbs), antibody based therapeutics are gaining increased attention from both large and small pharmaceutical companies. The Y-arm of the antibody is known as Fab, comprising a constant and a variable domain from each light and heavy chain. The variable domain (Fv) within the Fab region is responsible for target specificity and binding affinity whereas the base of the antibody, known as the fragment crystallizable (Fc) region, is responsible for interaction with immune cells. Modifications made in the Fc region can alter its effector functions. The key changes made in the Fc domain to improve the effector functions include glycoengineering, protein engineering or isotype chimerism. This can result in improvement in the ADCC activity, CDC activity, ADCP activity and half-life of the molecule.

The concept of engineered antibodies is widely being used for development for biobetters/biosimilars, addressing the drawbacks of their ancestor drug candidates. Several players have developed and made available their proprietary technologies for production of such engineered antibodies. This has encouraged and opened an opportunity for a large amount of licensing activity in this domain, building a strong collaborative network of small and big pharmaceutical companies.

Currently, two drugs, namely Gazyva® and POTELIGEO®, are commercially available. A number of molecules are being tested primarily for oncological indications; in addition, a limited set of molecules are also being developed for non-oncological indications such as asthma, COPD, neuromyelitis optica, ulcerative colitis and hemolytic disease in the newborn. Such initiatives suggest that the overall market is likely to hold a strong potential in the coming years.

Synopsis

The "Fc Protein and Glycoengineered Antibodies Market (2nd Edition), 2016-2026" report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs for addressing several oncology and non-oncological disorders. This market has steadily evolved over the last few years. The report examines several elements of developing these next generation antibodies, such as the technologies used for their production, site of engineering in an antibody and a robust landscape in the form of clinical / preclinical pipeline. For the purposes of this report, engineered antibodies are defined as antibodies that have been modified in their Fc region. The two types of modification considered include:

  • Fc Glycoengineering (referred to as 'Glycoengineering' in the report)
  • Fc Protein engineering

As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market. This was done by analyzing:

  • The Fc protein and glycoengineered antibody pipeline in terms of phase of development, type of therapy (monotherapy or combination therapy) and target indications.
  • Technologies established by various players for development of engineered antibody therapeutics including the key mechanism involved, licencing activity, advantages and the molecules being developed using the technology.
  • Partnerships that have taken place in the recent past covering technology licensing, product development and commercialization agreements, clinical trial collaborations, product license agreements, acquisitions and other relevant agreements.
  • Inherent threats to growth in the short and long term.
  • The likely adoption of the Fc protein and glycoengineered antibodies by understanding the competition posed by the current treatment plans and the expected growth rate over the coming few years.

The study provides a detailed market forecast and opportunity analysis for the short-mid term (2016-2021) and long term (2021-2026). The research, analysis and insights presented in this report include potential sales of the approved drugs and the ones in late stages of development (phase III). To add robustness to our model, we have provided three scenarios for our market forecast; these include the conservative, base and optimistic scenarios. Our opinions and insights, presented in this study were influenced by several discussions we conducted with experts in this area. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. Overall, we have identified nearly 70 products in marketed, clinical and preclinical stages of development; nearly 60% of the pipeline accounts for molecules in clinical development.
  • 2. The market is characterized by the presence of both small and big pharma players. Notable examples of small to mid-sized firms include (in alphabetical order) arGEN-X, Celldex Therapeutics, Clovis Oncology, Five Prime Therapeutics, Genmab, Immune Design, MorphoSys, TG Therapeutics and Zymeworks. The larger companies in the domain include Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Roche/Genentech, Kyowa Hakko Kirin and Merck.
  • 3. Several firms have also developed their proprietary technologies for Fc optimization and glycoengineering monoclonal antibodies. Examples include (in alphabetical order) BioWa with its POTELLIGENT® technology, Glycart with its GlycoMab Technology, Glycotope with its GlycoExpress™, ProBioGen with its GlymaxX® technology and Xencor with its XmAb Fc technology.
  • 4. Encouraging clinical results and prospects in multiple disease areas have yielded an intense framework of collaborative and licensing activity in this field. In fact, between 2005 and February 2016, there have been over 80 collaborations in this space.
  • 5. With two approved drugs, the glycoengineered antibodies are likely to emerge as the forerunner in the short term (84% of the market share by 2021). Subsequently, the Fc protein engineered antibodies are likely to garner a higher proportion (55% by 2026); specifically, Atezolizumab (by Roche) and Durvalumab (by AstraZeneca/MedImmune) are expected to be blockbusters.
  • 6. The overall market is anticipated to grow aggressively at a healthy annual growth rate of over 40% between 2016 and 2026. In the longer term, we expect the market to continue to rise steadily with high adoption rates of marketed drugs and approval of new drugs and indications.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the report. It offers a high level view on where the Fc protein and glycoengineering antibodies market is headed in the mid to long term.

Chapter 3 maps the historical evolution of monoclonal antibodies and provides a general introduction to the underlying concepts of antibody based therapeutics. This covers details about the structure of antibodies and techniques used to optimize/engineer them. In addition to this, we have also briefly discussed advantages of engineered antibodies over traditional therapeutic

Chapter 4 includes information on nearly 70 molecules that are approved and are being evaluated in different stages of development (both clinical and preclinical/discovery). In this chapter, we have identified the companies that are active in this market and conducted a detailed pipeline analysis including information on type of therapy (monotherapy/combination therapy), most commonly targeted indications and the phase of development.

Chapter 5 focuses on the glycoengineered antibodies market. It gives comprehensive profiles of the marketed, phase III and phase II drug candidates with a detailed understanding on the history of development, mechanism of action, clinical development status and key clinical trial results. Furthermore, we have provided a brief overview on the companies developing these molecules.

Chapter 6 provides information on the Fc protein engineered antibodies market. We have profiled phase II drug candidates with a detailed understanding on the history of development, mechanism of action, clinical development status and key clinical trial results. Furthermore, we have provided a brief overview on the companies developing these molecules.

Chapter 7 gives a comprehensive view on the market forecast measuring the opportunity in the short mid-term (2016-2021) and the long term (2021-2026). We have presented the key assumptions, forecast methodology and corresponding sales forecast output for different target indications. In addition, we have highlighted the relative contribution of the approved, phase III and phase II/III Fc protein and glycoengineered molecules individually.

Chapter 8 highlights the key technologies available for the production of engineered antibodies. We aim to review the advantages of each technology in detail and analyze the licensing activity in the recent past.

Chapter 9 features an elaborate discussion on the collaborations and partnerships that have been forged amongst players in this market. We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.

Chapter 10 provides our analysis of the market under the SWOT framework. This section identifies key elements that are likely to influence future growth and/or impede the progress.

Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Monoclonal Antibody
    • 3.2.1. How Monoclonal Therapy Works?
    • 3.2.2. Parts of a Monoclonal Antibody
    • 3.2.3. Fc Region and Effector Functions
    • 3.2.4. Types of Fc Receptors
    • 3.2.5. Engineering of the Fc Region
      • 3.2.5.1. Glycoengineering
      • 3.2.5.2. Protein Engineering
      • 3.2.5.3. Isotype Chimerism
  • 3.3. Antibody Based Therapeutics
    • 3.3.1. Approved Antibody Therapies: Distribution by Year of Approval
  • 3.4. Advantages of Engineered Antibodies

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Glycoengineered Antibodies: Development Pipeline
    • 4.2.1. Distribution by Phase of Development
    • 4.2.2. Distribution by Type of Indication
    • 4.2.3. Distribution by Type of Therapy
    • 4.2.4. Leading Players of the Industry
  • 4.3. Fc Protein Engineered Antibodies: Development Pipeline
    • 4.3.1. Distribution by Phase of Development
    • 4.3.2. Distribution by Type of Indication
    • 4.3.3. Distribution by Type of Therapy
    • 4.3.4. Distribution by Type of Effector Function
    • 4.3.5. Leading Players of the Industry

5. GLYCOENGINEERED ANTIBODIES MARKET

  • 5.1. Chapter Overview
  • 5.2. Kyowa Hakko Kirin
    • 5.2.1. Company Overview
    • 5.2.2. Financial Performance
    • 5.2.3. Product Profile: Mogamulizumab (POTELIGEO®/KW-0761)
      • 5.2.3.1. Drug Specification
      • 5.2.3.2. Mechanism of Action
      • 5.2.3.3. History of Development
      • 5.2.3.4. Current Status of Development
      • 5.2.3.5. Clinical Studies
      • 5.2.3.6. Key Clinical Trial Results
      • 5.2.3.7. Dosage Regimen and Sales Strategies
    • 5.2.4. Product Profile: Benralizumab (KHK4563/MEDI-563)
      • 5.2.4.1. Drug Specification
      • 5.2.4.2. Mechanism of Action
      • 5.2.4.3. History of Development
      • 5.2.4.4. Current Status of Development
      • 5.2.4.5. Clinical Studies
      • 5.2.4.6. Key Clinical Trial Results
    • 5.2.5. Product Profile: KHK4083
      • 5.2.5.1. Drug Specification
      • 5.2.5.2. Current Status of Development
      • 5.2.5.3. Clinical Studies
  • 5.3. Roche
    • 5.3.1. Company Overview
    • 5.3.2. Financial Performance
    • 5.3.3. Product Profile: Obinutuzumab (Gazyva®/GA101/RG7159)
      • 5.3.3.1. Drug Specification
      • 5.3.3.2. Mechanism of Action
      • 5.3.3.3. History of Development
      • 5.3.3.4. Current Status of Development
      • 5.3.3.5. Clinical Studies
      • 5.3.3.6. Key Clinical Trial Results
      • 5.3.3.7. Prescribing Information and Dosing Regimen
  • 5.4. TG Therapeutics
    • 5.4.1. Company Overview
    • 5.4.2. Financial Performance
    • 5.4.3. Product Profile: Ublituximab/TG-1101/LFB-R603
      • 5.4.3.1. Drug Specification
      • 5.4.3.2. Mechanism of Action
      • 5.4.3.3. History of Development
      • 5.4.3.4. Current Status of Development
      • 5.4.3.5. Clinical Studies
      • 5.4.3.6. Key Clinical Trial Results
  • 5.5. MedImmune/AstraZeneca
    • 5.5.1. Company Overview
    • 5.5.2. Financial Performance
    • 5.5.3. Product Profile: MEDI-551
      • 5.5.3.1. Drug Specification
      • 5.5.3.2. Mechanism of Action
      • 5.5.3.3. History of Development
      • 5.5.3.4. Current Status of Development
      • 5.5.3.5. Clinical Studies
      • 5.5.3.6. Key Clinical Trial Results
  • 5.6. LFB Biotechnologies
    • 5.6.1. Company Overview
    • 5.6.2. Financial Performance
    • 5.6.3. Product Profile: Roledumab/LFB-R593
      • 5.6.3.1. Drug Specification
      • 5.6.3.2. Mechanism of Action
      • 5.6.3.3. History of Development
      • 5.6.3.4. Current Status of Development
      • 5.6.3.5. Clinical Studies
  • 5.7. Glycotope
    • 5.7.1. Company Overview
    • 5.7.2. Product Profile: PankoMab-GEX™ (GT-MAB 2.5-GEX™)
      • 5.7.2.1. Drug Specification
      • 5.7.2.2. Mechanism of Action
      • 5.7.2.3. History of Development
      • 5.7.2.4. Current Status of Development
      • 5.7.2.5. Clinical Studies
      • 5.7.2.6. Key Clinical Trial Results
    • 5.7.3. Product Profile: CetuGEX™ (GT-MAB 5.2-GEX™)
      • 5.7.3.1. Drug Specification
      • 5.7.3.2. Mechanism of Action
      • 5.7.3.3. History of Development
      • 5.7.3.4. Current Status of Development
      • 5.7.3.5. Clinical Studies
      • 5.7.3.6. Key Clinical Trial Results

6. Fc ENGINEERED ANTIBODIES MARKET

  • 6.1. Chapter Overview
  • 6.2. Roche/Genentech
    • 6.2.1. Company Overview
    • 6.2.2. Product Profile: Atezolizumab (MPDL3280A/RG7446)
      • 6.2.2.1. Drug Specification
      • 6.2.2.2. Mechanism of Action
      • 6.2.2.3. History of Development
      • 6.2.2.4. Current Status of Development
      • 6.2.2.5. Clinical Studies
      • 6.2.2.6. Key Clinical Trial Results
  • 6.3. Astra Zeneca/MedImmnune
    • 6.3.1. Company Overview
    • 6.3.2. Product Profile: Durvalumab (MEDI 4736)
      • 6.3.2.1. Drug Specification
      • 6.3.2.2. Mechanism of Action
      • 6.3.2.3. History of Development
      • 6.3.2.4. Current Status of Development
      • 6.3.2.5. Clinical Studies
      • 6.3.2.6. Key Clinical Trial Results
  • 6.4. Mentrik Biotech
    • 6.4.1. Company Overview
    • 6.4.2. Drug Profile: Ocaratuzumab (AME-133V/ LY2469298)
      • 6.4.2.1. Drug Specification
      • 6.4.2.2. Mechanism of Action
      • 6.4.2.3. History of Development
      • 6.4.2.4. Current Status of Development
      • 6.4.2.5. Key Clinical Trial Results
  • 6.5. MacroGenics
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Drug Profile: Margetuximab (MGAH22)
      • 6.5.3.1. Drug Specification
      • 6.5.3.2. Mechanism of Action
      • 6.5.3.3. History of Development
      • 6.5.3.4. Current Status of Development
      • 6.5.3.5. Clinical Studies
      • 6.5.3.6. Key Clinical Trial Results
    • 6.5.4. Drug Profile: Teplizumab (MGA031/HOKT3Γ 1 (ALA-ALA))
      • 6.5.4.1. Drug Specification
      • 6.5.4.2. Mechanism of Action
      • 6.5.4.3. History of Development
      • 6.5.4.4. Current Status of Development
      • 6.5.4.5. Clinical Studies
      • 6.5.4.6. Key Clinical Trial Results
  • 6.6. Janssen Biotech (Johnson and Johnson)
    • 6.6.1. Company Overview
    • 6.6.2. Financial Performance
    • 6.6.3. Drug Profile: JNJ-56022473
      • 6.6.3.1. Drug Specification
      • 6.6.3.2. Mechanism of Action
      • 6.6.3.3. History of Development
      • 6.6.3.4. Current Status of Development
      • 6.6.3.5. Clinical Studies
      • 6.6.3.6. Key Clinical Trial Results
  • 6.7. MorphoSys
    • 6.7.1. Company Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Product Profile: MOR208
      • 6.7.3.1. Drug Specification
      • 6.7.3.2. Mechanism of Action
      • 6.7.3.3. History of Development
      • 6.7.3.4. Current Status of Development
      • 6.7.3.5. Clinical Studies
      • 6.7.3.6. Key Clinical Trial Results

7. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Limitations
  • 7.3. Forecast Methodology
  • 7.4. Overall Fc Protein and Glycoengineered Antibodies Market
  • 7.5. Glycoengineered Antibodies Market Forecast
    • 7.5.1. POTELIGEO® (Kyowa Hakko Kirin)
      • 7.5.1.1. Target Patient Population
      • 7.5.1.2. Sales Forecast
    • 7.5.2. Gazyva® (Roche/Genentech)
      • 7.5.2.1. Target Patient Population
      • 7.5.2.2. Sales Forecast
    • 7.5.3. Benralizumab (AstraZeneca)
      • 7.5.3.1. Target Patient Population
      • 7.5.3.2. Sales Forecast
    • 7.5.4. Ublituximab (TG Therapeutics)
      • 7.5.4.1. Target Patient Population
      • 7.5.4.2. Sales Forecast
    • 7.5.5. Roledumab (LFB Biotechnologies)
      • 7.5.5.1. Target Patient Population
      • 7.5.5.2. Sales Forecast
    • 7.5.6. MEDI-551 (MedImmune)
      • 7.5.6.1. Target Patient Population
      • 7.5.6.2. Sales Forecast
  • 7.6. Fc Protein Engineered Antibodies Market Forecast
    • 7.6.1. Atezolizumab (Roche)
      • 7.6.1.1. Target Patient Population
      • 7.6.1.2. Sales Forecast
    • 7.6.2. Durvalumab (MedImmune)
      • 7.6.2.1. Target Patient Population
      • 7.6.2.2. Sales Forecast
    • 7.6.3. Ocaratuzumab (Mentrik Biotech)
      • 7.6.3.1. Target Patient Population
      • 7.6.3.2. Sales Forecast
    • 7.6.4. Margetuximab (MacroGenics)
      • 7.6.4.1. Target Patient Population
      • 7.6.4.2. Sales Forecast
    • 7.6.5. MOR208 (MorphoSys)
      • 7.6.5.1. Target Patient Population
      • 7.6.5.2. Sales Forecast

8. TECHNOLOGICAL PLATFORMS FOR DEVELOPING ENGINEERED ANTIBODIES

  • 8.1. Chapter Overview
  • 8.2. POTELLIGENT® (BioWa, Subsidiary of Kyowa Hakko Kirin)
    • 8.2.1. Overview
    • 8.2.2. The Technology
    • 8.2.3. Discovery of POTELLIGENT® Technology
    • 8.2.4. Advantages of POTELLIGENT® Technology
    • 8.2.5. POTELLIGENT® CHOK1SV: A 2-in-1 Technology
    • 8.2.6. Drugs Based on POTELLIGENT® Technology
    • 8.2.7. Technology Licensees
    • 8.2.8. Product Alliances
      • 8.2.8.1. Amgen
      • 8.2.8.2. Teva Pharmaceuticals
      • 8.2.8.3. MedImmune
  • 8.3. GlycoMab Technology (GlycArt)
    • 8.3.1. Overview
    • 8.3.2. The Technology
    • 8.3.3. Advantages of GlycoMab Technology
    • 8.3.4. Drugs Based on GlycoMab Technology
  • 8.4. GlycoExpress™ (Glycotope)
    • 8.4.1. Overview
    • 8.4.2. The Technology
    • 8.4.3. Advantages of GlycoExpress™ Technology
    • 8.4.4. Drugs Based on GlycoExpress™ Technology
  • 8.5. GlymaxX® Technology (ProBioGen)
    • 8.5.1. Overview
    • 8.5.2. The Technology
    • 8.5.3. Advantages of GlymaxX® Technology
    • 8.5.4. Drugs Based on GlymaxX® Technology
    • 8.5.5. Technology Licensees
  • 8.6. XmAb® Antibody Technology (Xencor)
    • 8.6.1. Overview
    • 8.6.2. The Technology
    • 8.6.3. Drugs Based on XmAb® Antibody Technology
    • 8.6.4. Technology Licensees
    • 8.6.5. Product Alliances
      • 8.6.5.1. Amgen
      • 8.6.5.2. MorphoSys
  • 8.7. Other Fc Engineering Technologies
    • 8.7.1. EMABling® Technology (LFB)
    • 8.7.2. BryoTechnology (Greenovation Biotech)
    • 8.7.3. MAGE 1.5 (Eureka Therapeutics)
    • 8.7.4. Sugar Engineered Antibody (Seattle Genetics)
    • 8.7.5. Other Technologies

9. RECENT DEVELOPMENTS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models/Agreements
  • 9.3. Recent Collaborations
  • 9.4. Recent Collaborations: Distribution by Month /Year
  • 9.5. Recent Collaborations: Distribution by Type of Model for Therapeutic Applications
  • 9.6. Recent Collaborations: Distribution by Type of Product
  • 9.7. Recent Collaborations: Most Active Companies with Multiple Collaborations

10. SWOT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Strengths
  • 10.3. Weaknesses
  • 10.4. Opportunities
  • 10.5. Threats

11. CONCLUSION

  • 11.1. A Healthy Pipeline with Several Molecules in Late Stages of Development
  • 11.2. Engineered Antibodies: A Platform for Development of Biobetters
  • 11.3. With Established Technologies, the Companies are Steadily Broadening Their Pipeline
  • 11.4. Increasing Partnerships: An Attractive Opportunity for Several Pharma Players
  • 11.5. The Overall Market Offers a Huge Potential for Growth
  • 11.6. Concluding Remarks

12. INTERVIEW TRANSCRIPTS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1 Monoclonal Antibodies Nomenclature: Based on Type of Origin
  • Figure 3.2 Monoclonal Antibody Therapy: Mechanism of Action
  • Figure 3.3 Structure of Antibody
  • Figure 3.4 Types of Fc Region Modification
  • Figure 3.5 Approved Antibody Therapies: Distribution by Year of Approval
  • Figure 4.1 Glycoengineered Antibodies Pipeline: Distribution by Phase of Development
  • Figure 4.2 Glycoengineered Antibodies Pipeline: Distribution by Type of Indication
  • Figure 4.3 Glycoengineered Antibodies Pipeline: Distribution by Type of Therapy
  • Figure 4.4 Glycoengineered Antibodies Pipeline: Leading Players
  • Figure 4.5 Fc Protein Engineered Antibodies Pipeline: Distribution by Phase of Development
  • Figure 4.6 Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Indication
  • Figure 4.7 Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Therapy
  • Figure 4.8 Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Effector Function
  • Figure 4.9 Fc Protein Engineered Antibodies Pipeline: Leading Players
  • Figure 5.1 Kyowa Hakko Kirin: Annual Sales, 2011-2015 (JPY Million)
  • Figure 5.2 Mogamulizumab: History of Development
  • Figure 5.3 Benralizumab: History of Development
  • Figure 5.4 Roche: Annual Sales, 2011-2015 (CHF Billion)
  • Figure 5.5 Roche Annual Sales, 2015: Distribution by Business Segment (CHF Billion, %)
  • Figure 5.6 Obinutuzumab: Annual Sales, 2013-2015 (CHF Million)
  • Figure 5.7 Obinutuzumab: History of Development
  • Figure 5.8 Ublituximab: History of Development
  • Figure 5.9 AstraZeneca: Annual Sales, 2011-2015 (USD Million)
  • Figure 5.10 LFB Biotechnologies: Annual Sales, 2012-2014 (EUR Million)
  • Figure 6.1 Atezolizumab: History of Development
  • Figure 6.2 Durvalumab: History of Development
  • Figure 6.3 MacroGenics: Annual Sales 2011-2015 (USD Million)
  • Figure 6.4 Johnson and Johnson: Annual Sales 2011-2015 (USD Million)
  • Figure 6.5 MorphoSys: Annual Sales 2011-2015 (EUR Million)
  • Figure 7.1 Overall Fc Protein and Glycoengineered Antibodies Market (USD Million): 2016-2026 (Base Scenario)
  • Figure 7.2 Evolution of Fc Protein and Glycoengineered Antibodies Market: 2016, 2021 and 2026 (Base Scenario, USD Million)
  • Figure 7.3 Glycoengineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.4 Glycoengineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.5 Glycoengineered Antibodies Market, 2026: Distribution of Therapeutic Areas (USD Million, %)
  • Figure 7.6 POTELIGEO® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.7 POTELIGEO® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.8 Gazyva® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.9 Gazyva® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.10 Benralizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.11 Benralizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.12 Ublituximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.13 Ublituximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.14 Roledumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.15 Roledumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.16 MEDI-551 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.17 MEDI-551 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.18 Fc Protein Engineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.19 Fc Protein Engineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.20 Atezolizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.21 Atezolizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.22 Durvalumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.23 Durvalumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.24 Ocaratuzumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.25 Ocaratuzumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.26 Margetuximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.27 Margetuximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 7.28 MOR208 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Figure 7.29 MOR-208 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Figure 9.1 Recent Collaborations: Distribution by Year
  • Figure 9.2 Recent Collaborations: Distribution by Type of Model
  • Figure 9.3 Recent Collaborations: Distribution by Type of Product
  • Figure 9.4 Recent Collaborations: Distribution by Company
  • Figure 11.1 Fc Protein and Glycoengineered Antibodies Market: Top Players
  • Figure 11.2 Overall Fc Protein and Glycoengineered Antibodies Market Summary (USD Million): 2016, 2021, 2026

List of Tables

  • Table 3.1 Features of Engineered Fc Regions
  • Table 3.2 List of Approved Antibody Therapies
  • Table 4.1 Glycoengineered Antibodies: Marketed and Development Pipeline
  • Table 4.2 Fc Protein Engineered Antibodies: Development Pipeline
  • Table 5.1 Glycoengineered Antibodies: Profiled Drugs
  • Table 5.2 Mogamulizumab: Orphan Drug Designation
  • Table 5.3 Mogamulizumab: Current Status of Development
  • Table 5.4 Mogamulizumab: Clinical Trials
  • Table 5.5 Mogamulizumab: Clinical Trial Endpoints (Hematological Cancer)
  • Table 5.6 Mogamulizumab: Clinical Trial Endpoints (Solid Tumors)
  • Table 5.7 Benralizumab: Current Status of Development
  • Table 5.8 Benralizumab: Clinical Trials
  • Table 5.9 Benralizumab: Clinical Trial Endpoints (COPD)
  • Table 5.10 Benralizumab: Clinical Trial Endpoints (Asthma)
  • Table 5.11 KHK4083: Current Status of Development
  • Table 5.12 KHK4083: Clinical Trials
  • Table 5.13 Obinutuzumab: Current Status of Development
  • Table 5.14 Obinutuzumab: Industry Sponsored Clinical Trials
  • Table 5.15 Obinutuzumab: Non-Industry Sponsored Clinical Trials
  • Table 5.16 Obinutuzumab: Phase II and Above Clinical Trial Endpoints (CLL)
  • Table 5.17 Obinutuzumab: Phase I and I/II Clinical Trial Endpoints (CLL)
  • Table 5.18 Obinutuzumab: Clinical Trial Endpoints (NHL)
  • Table 5.19 Obinutuzumab: Clinical Trial Endpoints (DLBCL and/or FL)
  • Table 5.20 Obinutuzumab: Clinical Trial Endpoints (Non-Oncological Indications)
  • Table 5.21 Obinutuzumab: CLL11 Trial Results
  • Table 5.22 Gazyva®: Dosage Regimen
  • Table 5.23 Ublituximab: Current Status of Development
  • Table 5.24 Ublituximab: Clinical Trials
  • Table 5.25 Ublituximab: Clinical Trial Endpoints (CLL)
  • Table 5.26 Ublituximab: Clinical Trial Endpoints (B-Cell Malignancies)
  • Table 5.27 MEDI-551: Current Status of Development
  • Table 5.28 MEDI-551: Clinical Trials
  • Table 5.29 MEDI-551: Clinical Trial Endpoints (Oncological Indications)
  • Table 5.30 MEDI-551: Clinical Trial Endpoints (Non-Oncological Indications)
  • Table 5.31 Roledumab: Current Status of Development
  • Table 5.32 Roledumab: Clinical Trials
  • Table 5.33 PankoMab-GEX™: Current Status of Development
  • Table 5.34 PankoMab-GEX™: Clinical Trials
  • Table 5.35 PankoMab-GEX™: Clinical Trial Endpoints
  • Table 5.36 CetuGEX™: Current Status of Development
  • Table 5.37 CetuGEX™: Clinical Trials
  • Table 5.38 CetuGEX™: Clinical Trial Endpoints
  • Table 6.1 Fc engineered Antibodies: Profiled Drugs
  • Table 6.2 Atezolizumab: Current Status of Development
  • Table 6.3 Atezolizumab: Industry Sponsored Clinical Trials
  • Table 6.4 Atezolizumab: Non-Industry Sponsored Clinical Trials
  • Table 6.5 Atezolizumab: Phase III Clinical Trial Endpoints (NSCLC)
  • Table 6.6 Atezolizumab: Phase III Clinical Trial Endpoints (Other Oncological Indications)
  • Table 6.7 Durvalumab: Current Status of Development
  • Table 6.8 Durvalumab: Industry Sponsored Clinical Trials
  • Table 6.9 Durvalumab: Non-Industry Sponsored Clinical Trials
  • Table 6.10 Durvalumab: Phase III Clinical Trial Endpoints (NSCLC)
  • Table 6.11 Durvalumab: Phase III Clinical Trial Endpoints (Other Oncological Indications)
  • Table 6.12 Ocaratuzumab: Current Status of Development
  • Table 6.13 Margetuximab: Current Status of Development
  • Table 6.14 Margetuximab: Industry/Non-Industry Clinical Trials
  • Table 6.15 Margetuximab: Clinical Trial Endpoints
  • Table 6.16 Teplizumab: Clinical Trials
  • Table 6.17 JNJ-56022473: Clinical Trials
  • Table 6.18 MOR208: Current Status of Development
  • Table 6.19 MOR208: Clinical Trials
  • Table 6.20 MOR208: Clinical Trial Endpoints
  • Table 7.1 Fc Protein and Glycoengineered Antibodies: Market Potential of Candidates
  • Table 7.2 Poteligio®: Target Patient Population
  • Table 7.4 Benralizumab: Target Patient Population
  • Table 7.5 Ublituximab: Target Patient Population
  • Table 7.6 Roledumab: Target Patient Population
  • Table 7.7 MEDI-551: Target Patient Population
  • Table 7.8 Atezolizumab: Target Patient Population
  • Table 7.9 Durvalumab: Target Patient Population
  • Table 7.10 Ocaratuzumab: Target Patient Population
  • Table 7.11 Margetuximab: Target Patient Population
  • Table 7.12 MOR208: Target Patient Population
  • Table 8.1 Technology Platforms for Development of Engineered Antibodies
  • Table 8.2 POTELLIGENT®: Drugs Candidates
  • Table 8.3 Drugs Based on POTELLIGENT® Technology: Latest Updates
  • Table 8.4 POTELLIGENT®: Technology Licensing Agreements
  • Table 8.5 Comparison of Kd for Rituximab and Obinutuzumab
  • Table 8.6 GlycoMab Technology: Drug Candidates
  • Table 8.7 GlycoExpress™: Glycosylation Parameters
  • Table 8.8 GlycoExpress™: Drug Candidates
  • Table 8.9 GlymaxX®: Drug Candidates
  • Table 8.10 Drugs Based on GlymaxX® Technology: Latest Updates
  • Table 8.11 GlymaxX®: Technology Licensing Agreements
  • Table 8.12 XmAb®: Drug Candidates
  • Table 8.13 Drugs Based on XmAb® Antibody Technology: Latest Updates
  • Table 8.14 XmAb®: Technology Licensing Agreements
  • Table 8.15 EMABling®: Drug Candidates
  • Table 9.1 Fc Protein and Glycoengineered Antibodies: Recent Collaborations (2005-2016)
  • Table 10.1 SWOT Analysis of Engineered Antibodies Market
  • Table 13.1 Approved Antibody Therapies: Distribution by Year of Approval
  • Table 13.2 Glycoengineered Antibodies Pipeline: Distribution by Phase of Development
  • Table 13.3 Glycoengineered Antibodies Pipeline: Distribution by Type of Indication
  • Table 13.4 Glycoengineered Antibodies Pipeline: Distribution by Type of Therapy
  • Table 13.5 Glycoengineered Antibodies Pipeline: Leading Players
  • Table 13.6 Fc Protein Engineered Antibodies Pipeline: Distribution by Phase of Development
  • Table 13.7 Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Indication
  • Table 13.8 Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Therapy
  • Table 13.9 Fc Protein Engineered Antibodies Pipeline: Distribution by Type of Effector Function
  • Table 13.10 Fc Protein Engineered Antibodies Pipeline: Leading Players
  • Table 13.11 Kyowa Hakko Kirin: Annual Sales, 2011-2015 (JPY Million)
  • Table 13.12 Roche: Annual Sales, 2011-2015 (CHF Billion)
  • Table 13.13 Roche: Sales Distribution by Business Segment, 2015 (CHF Billion, %)
  • Table 13.14 Obinutuzumab: Annual Sales, 2013-2015 (CHF Million)
  • Table 13.15 AstraZeneca: Annual Sales, 2011-2015 (USD Million)
  • Table 13.16 LFB Biotechnologies: Annual Sales, 2012-2014 (EUR Million)
  • Table 13.17 MacroGenics: Annual Sales, 2011-2015 (USD Million)
  • Table 13.18 Johnson and Johnson: Annual Sales, 2011-2015 (USD Million)
  • Table 13.19 MorphoSys: Annual Sales, 2011-2015 (EUR million)
  • Table 13.20 Overall Fc Protein and Glycoengineered Antibodies Market (USD Million): 2016-2026 (Base Scenario)
  • Table 13.21 Overall Fc Protein and Glycoengineered Antibodies Market (USD Million): 2016-2026 (Optimistic Scenario)
  • Table 13.22 Overall Fc Protein and Glycoengineered Antibodies Market (USD Million): 2016-2026 (Conservative Scenario)
  • Table 13.23 Evolution of Fc Protein and Glycoengineered Antibodies Market: 2016, 2021 and 2026 (Base Scenario, USD Million)
  • Table 13.24 Glycoengineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.25 Glycoengineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.26 Glycoengineered Antibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.27 Glycoengineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.28 Glycoengineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.29 Glycoengineered Antibodies Market (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.30 Glycoengineered Antibodies Market, 2026: Share of Therapeutic Areas (USD Million, %)
  • Table 13.31 Poteligeo® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.32 Poteligeo® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.33 Poteligeo® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.34 Poteligeo® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.35 Poteligeo® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.36 Poteligeo® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.37 Gazyva® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.38 Gazyva® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.39 Gazyva® Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.40 Gazyva® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.41 Gazyva® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.42 Gazyva® Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.43 Benralizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.44 Benralizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.45 Benralizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.46 Benralizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.47 Benralizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.48 Benralizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.49 Ublituximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.50 Ublituximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.51 Ublituximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.52 Ublituximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.53 Ublituximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.54 Ublituximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.55 Roledumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.56 Roledumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.57 Roledumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.58 Roledumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.59 Roledumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.60 Roledumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.61 MEDI-551 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.62 MEDI-551 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.63 MEDI-551 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.64 MEDI-551 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.65 MEDI-551 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.66 MEDI-551 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.67 Fc Protein EngineeredAntibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.68 Fc Protein EngineeredAntibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.69 Fc Protein EngineeredAntibodies Market (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.70 Fc Protein EngineeredAntibodies Market (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.71 Fc Protein EngineeredAntibodies Market (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.72 Fc Protein EngineeredAntibodies Market (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.73 Atezolizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.74 Atezolizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.75 Atezolizumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.76 Atezolizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.77 Atezolizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.78 Atezolizumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.79 Durvalumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.80 Durvalumab Sales Forecast (USD Million), Long Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.81 Durvalumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.82 Durvalumab Sales Forecast (USD Million), Long Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.83 Durvalumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.84 Durvalumab Sales Forecast (USD Million), Long Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.85 Ocaratuzumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.86 Ocaratuzumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.87 Ocaratuzumab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.88 Ocaratuzumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.89 Ocaratuzumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.90 Ocaratuzumab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.91 Margetuximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.92 Margetuximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.93 Margetuximab Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.94 Margetuximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.95 Margetuximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.96 Margetuximab Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.97 MOR-208 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
  • Table 13.98 MOR-208 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
  • Table 13.99 MOR-208 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
  • Table 13.100 MOR-208 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
  • Table 13.101 MOR-208 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
  • Table 13.102 MOR-208 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
  • Table 13.103 Recent Collaborations: Distribution by Year
  • Table 13.104 Recent Collaborations: Distribution by Type of Model
  • Table 13.105 Recent Collaborations: Distribution by Type of Product
  • Table 13.106 Recent Collaborations: Distribution by Company
  • Table 13.107 Fc Protein and Glycoengineered Antibodies Market: Top Players
  • Table 13.108 Overall Fc Protein and Glycoengineered Antibodies Market Summary (USD Million): 2016, 2021, 2026

Listed Companies

The following companies and institutes have been mentioned in this report.

  • 1. AACR
  • 2. AbbVie
  • 3. ABN AMRO Capital
  • 4. Abramson Cancer Center of the University of Pennsylvania
  • 5. Advaxis
  • 6. Agensys
  • 7. Alexion Pharmaceuticals
  • 8. Amgen
  • 9. Applied Molecular Evolution
  • 10. Arana Therapeutics
  • 11. Archimedes Pharma
  • 12. arGEN-X
  • 13. AstraZeneca
  • 14. Avon Breast Cancer Foundation
  • 15. Bayer Healthcare
  • 16. Berlin-Chemie (Menarini Group)
  • 17. Biogen Idec
  • 18. BioMedinvest
  • 19. BioWa
  • 20. Boehringer Ingelheim
  • 21. Bristol-Myers Squibb
  • 22. Cambridge Antibody Technology
  • 23. Cancer Research Institute
  • 24. Cantargia
  • 25. Celgene
  • 26. Celldex Therapeutics
  • 27. Cellective Therapeutics
  • 28. Centocor Research and Development
  • 29. Chugai Pharmaceutical
  • 30. Clinical Cancer Research
  • 31. Columbia University Medical Center
  • 32. Committee for Medicinal Products for Human Use
  • 33. CSL Limited
  • 34. CTI BioPharma
  • 35. Cure Brain Cancer Foundation
  • 36. Daiichi Sankyo
  • 37. Dana-Farber Cancer Institute
  • 38. Deutsche Venture Capital
  • 39. Eisai
  • 40. Eli Lilly
  • 41. Eureka Therapeutics
  • 42. European Cancer Congress
  • 43. European Hematology Association
  • 44. Five Prime Therapeutics
  • 45. Fondazione Italiana Linfomi ONLUS
  • 46. Fountain BioPharma
  • 47. Fredrick Manufacturing Center
  • 48. GamaMabs Pharma
  • 49. Genentech
  • 50. Genitourinary Cancers Symposium of the American Society of Clinical Oncology
  • 51. Genzyme
  • 52. German Breast Group
  • 53. German CLL Study Group
  • 54. Gilde Investment Management
  • 55. GlaxoSmithKline
  • 56. Global Life Science Ventures
  • 57. GlycArt Biotechnology
  • 58. Glycode
  • 59. GlycoFi
  • 60. Glycotope Biotechnology
  • 61. Green Cross
  • 62. Greenovation Biotech
  • 63. GSK
  • 64. GTC Biotherapeutics
  • 65. Hoosier Cancer Research Network
  • 66. Human Genome Sciences
  • 67. Ildong Pharmaceutical
  • 68. ImmunoCellular Therapeutics
  • 69. Immunocore
  • 70. Incyte Corporation
  • 71. Inhibrx
  • 72. Institute of Cancer Research, United Kingdom
  • 73. Italian Network for Tumor Biotherapy Foundation
  • 74. Janssen Pharmaceuticals (Johnson & Johnson)
  • 75. Johannes Gutenberg University Mainz
  • 76. Juno Therapeutics
  • 77. Kairos Therapeutics
  • 78. KaloBios Pharmaceuticals
  • 79. King Faisal Specialist Hospital & Research Center
  • 80. Kolltan
  • 81. Kyowa Hakko Kirin
  • 82. Kyowa Hakko Kogyo
  • 83. LFB Biotechnologies
  • 84. Lonza
  • 85. Ludwig Institute for Cancer Research
  • 86. M.D. Anderson Cancer Center
  • 87. MacroGenics
  • 88. MedImmune
  • 89. Memorial Sloan Kettering Cancer Center
  • 90. Menarini
  • 91. Mentrik Biotech
  • 92. Merck
  • 93. Merus
  • 94. Mirati Therapeutics
  • 95. MorphoSys
  • 96. Nantes University Hospital
  • 97. Naomi Berrie Diabetes Center
  • 98. National Cancer Institute
  • 99. National Institute of Allergy and Infectious Diseases
  • 100. NCIC Clinical Trials Group
  • 101. NEMOD Biotherapeutics
  • 102. Neovii Biotech
  • 103. National Institutes of Health
  • 104. NKT Therapeutics
  • 105. NorthWestern University
  • 106. Novartis
  • 107. Novo Nordisk
  • 109. OncoTherapy Science
  • 110. Ono Pharmaceutical
  • 111. Orpegen Pharma
  • 112. Otsuka Pharmaceutical
  • 113. Oxford BioTherapeutics
  • 114. Parexel
  • 115. Peregrine Pharmaceuticals
  • 116. Pfizer
  • 117. Pharmaceuticals and Medical Devices Agency
  • 118. Pharmacyclics
  • 119. PRA Health Sciences
  • 120. PrECOG
  • 121. ProBioGen
  • 122. ProStrakan
  • 123. Queen Mary University of London
  • 124. Quester Capital Management
  • 125. Raven Biotechnologies
  • 126. Regeneron
  • 127. Roche
  • 128. Sanofi
  • 129. Seattle Genetics
  • 130. Servier
  • 131. Sidney Kimmel Comprehensive Cancer Center
  • 132. Sorrento Therapeutics
  • 133. Spectrum Pharmaceuticals
  • 134. Swiss Federal Institute of Technology
  • 135. Synimmune
  • 136. Synthon
  • 137. Takeda Pharmaceuticals
  • 138. Teva Pharmaceuticals
  • 139. TG Therapeutics
  • 140. Tiziana Life Sciences
  • 141. Tizona Therapeutics
  • 142. Tolerance Therapeutics
  • 143. UCB Pharma
  • 144. United Therapeutics
  • 145. University of Bern
  • 146. University of California, San Diego
  • 147. Ventana Medical Systems
  • 148. VentiRx Pharmaceuticals
  • 149. Xencor
  • 150. Zymeworks
Back to Top